PHAT — Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Revenues: $58.3 million, up 104% year-over-year from $28.5 million in Q1 2025, and a 1% increase sequentially from Q4 2025.
• Cash Operating Expenses: $56.2 million, reflecting disciplined expense management and a 43% decrease year-over-year compared to Q1 2025.
• Net Cash Usage: Approximately $15 million for Q1 operations.
• Gross Margin: Approximately 80%, consistent with guidance; gross-to-net discount at the lower end of the 55%-59% range due to channel mix.
• Prescriptions: 1.35 million VOQUEZNA prescriptions filled through April 17, 2026, with a significant increase in covered prescriptions (91% year-over-year growth).

2. Strategic Updates and Business Highlights:

• Phathom is focused on building a strong presence in gastroenterology, with nearly 290 sales representatives deployed to enhance outreach.
• The company aims for $1 billion in annual revenue from gastroenterology prescriptions, with a secondary target from primary care as patient awareness grows.
• VOQUEZNA has achieved approximately 45% new-to-brand prescription market share among top gastroenterology writers, indicating strong adoption.
• The company is preparing for a potential second P-CAB approval in the U.S. in 2027, with confidence in VOQUEZNA's clinical data profile.

3. Forward Guidance and Outlook:

• Maintaining 2026 revenue guidance of $320 million to $345 million, with expectations for revenue to be weighted towards the second half of the year.
• Anticipating cash operating expenses (excluding stock-based compensation) between $235 million to $255 million for the year.
• Projecting operating profitability (excluding stock-based compensation) by Q3 2026 and positive cash flow in 2027.

4. Bad News, Challenges, or Points of Concern:

• Q1 revenue was slightly below internal expectations due to market access seasonality and deployment timing of the sales force.
• The potential entry of a second P-CAB competitor could create market dynamics that may affect VOQUEZNA's market share, although management remains confident in their first-mover advantage and strong physician relationships.
• There are concerns regarding the gross-to-net dynamics, with fluctuations expected based on channel mix and cash pay prescriptions.

5. Notable Q&A Insights:

• Management acknowledged the competitive landscape with the upcoming second P-CAB entrant but emphasized their strong market share and physician confidence in VOQUEZNA.
• There is an ongoing evaluation of potential M&A opportunities to enhance their product portfolio, although no immediate urgency was indicated.
• Feedback from physicians regarding VOQUEZNA has been positive, with many reporting significant patient improvements, which is expected to drive future prescriptions.
• The company is observing a natural progression of physicians starting with severe cases and gradually expanding VOQUEZNA's use to less severe patients, indicating a potential for sustained growth.

Overall, Phathom Pharmaceuticals is demonstrating robust growth in revenues and prescriptions, with a clear strategy focused on gastroenterology, while navigating competitive pressures and maintaining a disciplined approach to expenses.